<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02745704</url>
  </required_header>
  <id_info>
    <org_study_id>3rd-SYSU-I-Cure</org_study_id>
    <nct_id>NCT02745704</nct_id>
  </id_info>
  <brief_title>The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg</brief_title>
  <official_title>The Optimizing Treatment of PegIFN Alfa in HBeAg-negative Chronic Hepatitis B Patients With Low Level HBsAg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanchang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huizhou Municipal Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital, Shunde China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen Third People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Foshan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Kunming Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yuebei People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As HBsAg clearance is uncommon in chronic hepatitis B (CHB) patients on nucleoside analogues
      (NAs) therapy. The purpose of this study is to optimize HBsAg clearance in CHB Patients with
      sequential treatment of pegylated interferon alpha and NAs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to optimize HBsAg clearance in CHB patients with low level HBsAg, the investigators
      enrolled patients who had received, and responded to, NAs for more than 12 months(see the
      inclusion criteria), and patients are switched to receive peginterferon alfa-2a 180
      micrograms/week or peginterferon alfa-2b 80 micrograms/week for 48 weeks and follow up for 24
      weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBsAg Clearance</measure>
    <time_frame>72 weeks</time_frame>
    <description>Percentage of Participants with HBsAg negative.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HBsAg Seroconversion</measure>
    <time_frame>72 weeks</time_frame>
    <description>Percentage of Participants with HBsAg negative and anti-HBsAg positive.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>PEG-IFN group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatitis B e antigen (HBeAg)-negative CHB patients who had received NAs for more than 12 months, with HBsAg &lt;1500 IU/ mL and Hepatitis B virus DNA not detectable, are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAs group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients do not need to change their NAs treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa</intervention_name>
    <description>peginterferon alfa-2b 80 micrograms/week or peginterferon alfa-2a 180 micrograms/week</description>
    <arm_group_label>PEG-IFN group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. CHB patients who had received NAs for more than 12 months.

          2. Hepatitis B e antigen (HBeAg)-negative and anti-HBeAg positive.

          3. Hepatitis B surface antigen (HBsAg) positive and &lt;1500 IU/mL.

          4. Hepatitis B virus DNA not detectable(Roche Cobas).

        Exclusion Criteria:

          1. Patients with liver cirrhosis, Hepatocellular Carcinoma or other malignancies.

          2. Patients with other factors causing liver diseases.

          3. Pregnant and lactating women.

          4. Patients with concomitant HIV infection or congenital immune deficiency diseases.

          5. Patients with diabetes, autoimmune diseases.

          6. Patients with important organ dysfunctions.

          7. Patients with serious complications (e.g., infection, hepatic encephalopathy,
             hepatorenal syndrome, gastrointestinal bleeding.)

          8. Patients who receive antineoplastic or immunomodulatory therapy in the past 12 months.

          9. Patients who can't come back to clinic for follow-up on schedule.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The third affiliated hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang Zhu, Doctor</last_name>
      <phone>13826452564</phone>
      <email>0628zhuxiang@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2016</study_first_submitted>
  <study_first_submitted_qc>April 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>May 20, 2018</last_update_submitted>
  <last_update_submitted_qc>May 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Zhiliang Gao</investigator_full_name>
    <investigator_title>chief director of department of infectious disease</investigator_title>
  </responsible_party>
  <keyword>chronic hepatitis B</keyword>
  <keyword>peginterferon alfa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

